This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Marcus M. Reidenberg, MD

JAMA. 1991;265(23):3107-3109.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The two principal themes of clinical pharmacology, individualization of drug therapy and the scientific assessment of drugs in humans, continue to be integrated into the mainstream of medicine itself.

The major development that is helping to individualize therapy is the continuing advance of pharmacogenetics and its application to clinical problems. The discovery that some people were very slow metabolizers of debrisoquin (a drug used to test a pathway of drug metabolism), because they lack the gene for the normal enzyme, has led to new interest in understanding the genetic basis of individual variation in drug response. Many drugs, including some tricyclic antidepressants (eg, desipramine, imipramine, nortriptyline, and amitriptyline) and propafenone, are metabolized by this pathway.¹ About 7% of the population is markedly deficient in this enzyme. Prescribing these tricyclic antidepressants for patients who have this enzyme deficiency can lead to high levels of the drugs and toxic effects at . . . [Full Text PDF of this Article]

Author Affiliations
Cornell University, New York, NY

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?